Efficacy comparison of subsequent treatment modalities for locally advanced hypopharyngeal cancer with partial response to neoadjuvant chemotherapy
10.3760/cma.j.cn115330-20250103-00006
- VernacularTitle:新辅助化疗后PR的中晚期下咽癌不同后续治疗方案的疗效比较
- Author:
Ru WANG
1
;
Zheng LI
;
Jugao FANG
;
Junfang XIAN
;
Qi ZHONG
;
Yang ZHANG
;
Lizhen HOU
;
Hongzhi MA
;
Ling FENG
;
Shizhi HE
;
Qian SHI
;
Yifan YANG
;
Haiyang LI
;
Lingwa WANG
;
Xinyu LI
Author Information
1. 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科，北京 100730
- Publication Type:Journal Article
- Keywords:
Hypopharyngeal neoplasms;
Carcinoma, squamous cell;
Neoadjuvant chemotherapy;
Partial response
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2025;60(10):1223-1231
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the survival outcomes of different subsequent treatment regimens in patients with locally advanced hypopharyngeal squamous cell carcinoma (HPSCC) who achieved partial response (PR) after neoadjuvant chemotherapy based on the gross tumor volume regression rate (GTVRR).Methods:This retrospective study included patients with locally advanced HPSCC treated at the Department of Head and Neck Surgery, Beijing Tongren Hospital, from January 2011 to December 2023. The cohort included 135 males and 3 females, aged from 35 to 77 years. All patients received 2-3 cycles of TPF regimen (paclitaxel+cisplatin+5-fluorouracil) neoadjuvant chemotherapy. Subsequent treatments included concurrent chemoradiotherapy or surgery combined with postoperative adjuvant radiotherapy. The impacts of different subsequent treatment modalities on the survivals and prognoses of patients were compared based on GTVRR thresholds of 50% and 70%. The χ 2 test was used to analyze influencing factors; survival analysis and intergroup comparisons were performed using the Kaplan-Meier method and Log-rank test; prognostic factors were assessed using univariate and multivariate Cox regression analyses. Results:The 5-year OS and PFS rates were 56.5% and 47.9%, respectively, while, the 10-year OS and PFS rates were 25.8% and 21.2%, respectively. The median OS was 75 months, and the median PFS was 48 months. The laryngeal function preservation rate for the entire cohort was 83.3%. The patients who underwent surgery combined with postoperative radiotherapy had significantly better OS and PFS outcomes than those treated with concurrent chemoradiotherapy ( P<0.05). Stratification based on GTVRR revealed that the surgery plus postoperative radiotherapy regimen was particularly effective for PR patients with a GTVRR of 30%-70%, showing significantly better OS and PFS compared to the concurrent chemoradiotherapy group ( P<0.05). Conclusion:The optimal subsequent treatment for PR-HPSCC may be surgery-based comprehensive treatment, particularly for patients with a GTVRR of 30%-70%. This study offers valuable insights for the stratified treatment of HPSCC, which could contribute to improving overall patient prognosis.
